Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2022;33(2):224-31
Article Links
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study
Lamia Oulkadi1, Samira Rostom1, Ihssane Hmamouchi2,3, Imane El Binoune1, Bouchra Amine1, Redouane Abouqal2, Lahsen Achemlal4, Fadoua Allali5, Imane El Bouchti6, Abdellah ElMaghraoui7, Imad Ghozlani8, Hasna Hassikou9, Taoufik Harzy10, Linda Ichchou11, Ouafae Mkinsi12, Redouane Niamane13, Rachid Bahiri1
Authors Information

1Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco

2Laboratory of Biostatistical, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco

3Department of Rheumatology, Provincial Hospital of Temara, Morocco

4Department of Rheumatology, Military Hospital Mohammed V, Ibn Sina University Hospital, Rabat, Morocco

5Department of Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, Salé, Morocco

6Department of Rheumatology, Arrazi University Hospital, Marrakech, Morocco

7Private Medical Office, Rabat, Morocco

8Department of Rheumatology, University Hospital of Agadir, Morocco

9. Department of Rheumatology, Military Hospital Moulay Ismail, Hassan II University Hospital, Meknès - Morocco.

10Department of Rheumatology, Hassan II University Hospital, Fès, Morocco.

11Department of Rheumatology, Mohammed VI University Hospital, Oujda, Morocco

12Department of Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco

13Department of Rheumatology, Military Hospital Avicenne, Mohammed VI University Hospital, Marrakech, Morocco

Keywords: methotrexate, rheumatoid arthritis, biotherapy registry, Morocco, rheumatology, therapeutic
References
  1. DP Symmons, MA Jones, DL Scott, P Prior. Long term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
  2. Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 2019;135-50.
  3. Smolen JS, Landewé R, Bijlsma J, Burmester G, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
  4. Pincus T, Gibson K A, Isabel C. Update on Methotrexate as the Anchor Drug for Rheumatoid Arthritis. Bull Hosp Jt Dis 2013; 71 Suppl 1:S9-19.
  5. Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. Adv Ther 2016;33:369-78.
  6. Bijlsma JW, Jacobs JW. Methotrexate: still the anchor drug in RA treatment. Joint Bone Spine 2009;76(5):452-4.
  7. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014(6):CD000957.
  8. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of   Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625–39.
  9. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis.2010;69(6):964-75.
  10. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72(12):1897-904.
  11. Hmamouchi I, Abouqal R, Achemlal L, Allali F, Bahiri R, El Bouchti I, et al. The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Rev Mar Rhum 2019;49:32-7.
  12. Dougados M, Nguyen M, Duchenne L, Benjelloun M, Amor B. Appréciation de l’utilité des traitements de fond de la polyarthrite rhumatoïde par l’analyse du taux de maintenance thérapeutique. Rev Rhum 1989;56:89-92.
  13. Pincus T, Marcum SB, Callahan LF. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
  14. Dougados M, Siney H, Amor B. Le méthotrexate dans la polyarthrite rhumatoide: appreciation de son utilité par l’analyse du taux de maintenance thérapeutique.Absract, Journées Provincilaes de la Sociéte Française de Rhumatologie- lImoges, Juin 1990 – Livre des Résumés: 15.
  15. Anaya JM, Jorgensen C, Daures JP, Combe B, Sany J. Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases. Rev Rhum 1992;59(3):181-7.
  16. Pavelka K, Forejtova S, Pavelkova A, Zvarova J, Rovensky J, Tuchynova A. Analysis of the reasons for DMARD therapy discontinuation in patients with Rheumatoid Arthritis in the Czech and Slovak republics. Clin Rheumatol 2002;21:220-36.
  17. Sany J, Anaya JM, Lussiez V, Couret M, Bernard C, Daures JP. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 1991;18(9):1323-27.
  18. Baccouche K, Fathallah N, Belghali S, Amri D, Elamri N, Brahim K. Etude rétrospective de l’efficacité à long terme, la tolérance et le maintien thérapeutique du Méthotrexate en monothérapie au cours de la polyarthrite rhumatoïde. Annales des sciences de la santé 2017;15(1):1-10.
  19. Bencharif I, Slimani S. Méthotrexate dans la polyarthrite rhumatoide. Maintien thérapeutique et tolérance dans la vraie vie chez les algériens: étude bicentrique. Rev Rhum 2014;81S:A138-A139.
  20. Latifa Tahiri, Fadoua Allali, Imane Jroundi, Radouane Abouqal,Najia Hajjaj-Hassouni .Therapeutic maintenance level of methotrexate in rheumatoid arthritis. Santé Jul-Sep. 2006;16(3):167-72.
  21. Bendriss N, Elmangad FZ, Aouial M, Rekkab I, Boujemaoui A, Belkhou A. Taux de maintenance thérapeutique de méthotrexate au cours de la polyarthrite rhumatoïde. Revue de rhumatisme 2012;79:S1.
  22. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease Modifying Antirheumatic Drugs in Early Rheumatoid Arthritis: A Longterm Observational Study. J Rheumatol 2002;29:261-6.
  23. Stouten V, Michiels S, Westhovens R, De Cock D, Belba A, Pazmino S, et al. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. Clin Rheumatol 2020;39:2593-601.
  24. Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, et al. Longterm Methotrexate use in Rheumatoid Arthritis : 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000;27:1864-71.
  25. Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive Rheumatoid Arthritis with Méthotrexate. J Rheumatol 1997;24:1881-9.
  26. Rau R, Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004;22(5 Suppl 35):S83-S94.
  27. Fürst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with Methotrexate during 176 weeks of a longterm prospective trial in patients with Rheumatoid Arthritis. J Rheumatol 1990;17:1658-735.
  28. Salaffi, Carotti M, Sartini A, Cervini C. A prospective study of the longterm efficacy and toxicity of low – dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 1995;13(1): 23-8.
  29. Hobl EL, Mader R M, Jilma B, Duhm B, Mustak M, et al. A Randomized, Double-Blind, Parallel, Single-Site Pilot Trial to Compare Two Different Starting Doses of Methotrexate in Methotrexate-Naïve Adult Patients with Rheumatoid Arthritis. Clin Ther 2012;34(5):1195-203.
  30. Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, et al. Longterm Methotrexate use in Rheumatoid Arthritis: 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000;27:1864-71.
  31. Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive Rheumatoid Arthritis with Méthotrexate. J Rheumatol 1997;24:1881-9.
  32. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step up combination therapy (methotrexate, cyclosporine A, sulphasalazine) or monotherapy for three years. Rheumatology 2002;41(8):892-8.
  33. Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human antitumor necrosis factor-α antibody compared with Methotrexate in longstanding Rheumatoid arthritis. Rheumatology 2002;41:430-39.
  34. El-Zorkany BK, Gamal SM, ElMofty SA. Frequency and causes of discontinuation of methotrexate in a cohort of Egyptian patients. Egypt Rheumatol 2013; 35(2):53-7.
  35. Alarcon GS, Tracy JC, Blackborn W.D. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1989;32:671-6.
  36. Slouma M, Saidane O, Mahmoud I, Tekaya R, Sahli H, Abdelmoula L. Motifs d’arrêt du méthotrexate au cours de la polyarthrite rhumatoide: étude d’une série tunisienne. Rev Rhum 2014;81S:A152.
  37. McWilliams DF, Kiely PDW, Young A, Walsh DA. Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. BMC Musculoskelet Disord 2013;14:153.
  38. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA.  Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? ClinExp Rheumatol 2005,23:861-6.
  39. Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA. Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol Int 2007;27:1057-61.